Daiichi Sankyo Company, Limited
4568.THealthcareTSEDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Daiichi Sankyo Company, Limited focuses on Drug Manufacturers - General services and products. Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company carries a $5.00T market cap, placing it firmly in the mega-cap category. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC.
Market Cap
$5.00T
Beta
-0.17
P/E (TTM)
19.60
P/E (Fwd)
19.15
EPS (TTM)
$140.31
EPS (Fwd)
$143.56
ROE
15.8%
ROA
3.8%
Cash
$449.81B
Total Debt
$300.48B
Free CF
-$225.47B
52W Change
-30.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $449.81B in cash comfortably exceeding the $300.48B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$225.47B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 15.8%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.04T (2022) to $1.89T (2025), reflecting a 81% increase over the period.
4568.T's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Daiichi Sankyo Company, Limited's trajectory.